Breast Fat Grafting vs Stem Cell Breast Augmentation
以下事实均来自两个条目页面及其出处。先对比双方都有记录的项，其余并排展示。
医疗
Breast Fat GraftingBreast fat grafting (fat transfer breast augmentation) uses the patient's own liposuctioned fat to modestly enlarge or reshape the breast without an implant.更新 2026年9月20日概念
Stem Cell Breast AugmentationA consumer and marketing term for breast fat grafting enriched with stromal vascular fraction or adipose-derived cells. It is not a separate regulated procedure category.更新 2026年9月21日两者的关系Breast Fat Grafting — 相关 → Stem Cell Breast Augmentation
共同项
双方均有记录 0 项这两项目前还没有共同记录的条目。各自已核实的事实见下方。
各自的事实
仅在其中一方有记录的已核实事实。
Breast Fat Grafting
DefinitionFat is taken by liposuction from other parts of the body and injected to enlarge the breasts
Typical donor sitesUsually the abdomen or flanks, though fat can be taken from almost anywhere (surgeon quoted by ASPS)
Typical size increaseSurgeon quoted by ASPS: ideal candidate wants half a cup to one cup; a larger increase may take two to three procedures
Listed risksCysts, infection, microcalcification, death of fat cells (necrosis), and some transferred fat leaving the breast area
Pre-expansion optionSurgeons may recommend an external tissue expansion system in the weeks before surgery
Pooled volume retention54% (95% CI 48.5–59.5%) across 25 studies, follow-up 3–36 months
Retention by fat preparation methodCentrifugation 51.5% vs sedimentation 38.7% pooled retention
Oncologic safety evidenceMeta-analysis of 15 studies (8,541 participants): no difference in overall survival, disease-free survival or local recurrence between patients who had fat grafting after breast cancer surgery and controls
1987 professional positionASPRS (predecessor of ASPS) condemned autologous fat injection for breast augmentation over concerns about cancer detection
2009 ASPS Fat Graft Task ForceConcluded that the literature then available showed no association between fat grafting and higher rates of malignancy
US regulatory statusFollowing FDA guidance issued in November 2017, autologous fat grafts do not require premarket approval; stromal vascular fraction products receive closer review
Relevant FDA guidanceSame Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception
Suitable forPeople wanting a relatively small increase in breast size who have enough donor fat (ASPS)
SessionsMore than one session may be needed because part of the graft is resorbed
Imaging noteFat necrosis, cysts and calcifications can appear on mammograms and must be interpreted by a radiologist
Stem Cell Breast Augmentation
尚无核实数据